-transparent.png){kind=logo}
Combination chemotherapy with epirubicin-cisplatin was employed after surgical treatment in 67 women with ovarian carcinoma. 50 mg/m2 of epirubicin and cisplatin each were administered at monthly intervals. The response rate was correlated with the clinical stage and the residual disease. Tumor regression (CR + PR) was observed in 63.6% of patients with stage III disease, and in 50% of those with stage IV disease. Furthermore, complete or partial responses were obtained in 86.4% of patients with a residual deposit of 2-5 cm, and in 33.3% of women with a residual deposit exceeding 5 cm in diameter. Anemia occurred in 47.8%, leukopenia in 43.3%, and thrombocytopenia in 4.5% of the patients. No cardiotoxicity was recorded.
L C Fuith, and
A Bazzanella, and
H Hetzel
October 1991,
Gynecologic oncology,
L C Fuith, and
A Bazzanella, and
H Hetzel
January 2014,
World journal of gastroenterology,
L C Fuith, and
A Bazzanella, and
H Hetzel
January 1992,
European journal of gynaecological oncology,
L C Fuith, and
A Bazzanella, and
H Hetzel
June 1989,
Tumori,
L C Fuith, and
A Bazzanella, and
H Hetzel
January 1985,
Cancer chemotherapy and pharmacology,
L C Fuith, and
A Bazzanella, and
H Hetzel
June 2003,
Anti-cancer drugs,
L C Fuith, and
A Bazzanella, and
H Hetzel
July 2004,
British journal of cancer,
L C Fuith, and
A Bazzanella, and
H Hetzel
August 2000,
Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
L C Fuith, and
A Bazzanella, and
H Hetzel
June 1998,
Hinyokika kiyo. Acta urologica Japonica,
L C Fuith, and
A Bazzanella, and
H Hetzel
March 1990,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
